Compare NHTC & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHTC | FEMY |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 37.2M |
| IPO Year | 1999 | 2021 |
| Metric | NHTC | FEMY |
|---|---|---|
| Price | $2.89 | $0.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 20.5K | ★ 426.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 14.44% | N/A |
| EPS Growth | N/A | ★ 8.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,776,000.00 | $1,629,108.00 |
| Revenue This Year | N/A | $59.47 |
| Revenue Next Year | N/A | $150.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 51.97 |
| 52 Week Low | $2.40 | $0.31 |
| 52 Week High | $5.48 | $1.63 |
| Indicator | NHTC | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 34.68 | 48.07 |
| Support Level | $2.71 | $0.54 |
| Resistance Level | $3.16 | $0.58 |
| Average True Range (ATR) | 0.17 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 16.22 | 46.13 |
Natural Health Trends Corp is an international direct-selling and e-commerce company. It offers a line of products such as Wellness, Herbal, Beauty, Lifestyle, and Home. Wellness products include targeted nutrition for joint health, antioxidant support, digestive health, heart health, and vision health. Herbal products include anti-aging and hydrating cleansers, creams, lotions, serums, and toners. Lifestyle products improve the overall quality of life and support active, physical, and healthy lifestyles. Home products are designed to create a clean and natural living environment for the home. It generates a majority of its revenue from Hong Kong and the rest from China, Taiwan, Japan, the United States, and other regions.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.